Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 124

1.

Metabolically programmed iron chelators.

Bergeron RJ, Bharti N, McManis JS, Wiegand J.

Bioorg Med Chem. 2015 Sep 1;23(17):5954-71. doi: 10.1016/j.bmc.2015.06.059. Epub 2015 Jun 29.

2.

Desferrithiocin: a search for clinically effective iron chelators.

Bergeron RJ, Wiegand J, McManis JS, Bharti N.

J Med Chem. 2014 Nov 26;57(22):9259-91. doi: 10.1021/jm500828f. Epub 2014 Sep 10. Review.

3.

Substituent effects on desferrithiocin and desferrithiocin analogue iron-clearing and toxicity profiles.

Bergeron RJ, Wiegand J, Bharti N, McManis JS.

J Med Chem. 2012 Aug 23;55(16):7090-103. doi: 10.1021/jm300509y. Epub 2012 Aug 13.

4.

Synthesis of Heterobactins A and B and Nocardia Heterobactin.

Bergeron RJ, Singh S, Bharti N.

Tetrahedron. 2011 May 6;67(18):3163-3169. Epub 2011 Mar 8.

5.

Desferrithiocin analogue iron chelators: iron clearing efficiency, tissue distribution, and renal toxicity.

Bergeron RJ, Wiegand J, Bharti N, McManis JS, Singh S.

Biometals. 2011 Apr;24(2):239-58. doi: 10.1007/s10534-010-9389-y. Epub 2010 Nov 20.

6.

The impact of polyether chain length on the iron clearing efficiency and physiochemical properties of desferrithiocin analogues.

Bergeron RJ, Bharti N, Wiegand J, McManis JS, Singh S, Abboud KA.

J Med Chem. 2010 Apr 8;53(7):2843-53. doi: 10.1021/jm9018146.

7.

Design, Synthesis, and Testing of Polyamine Vectored Iron Chelators.

Bergeron RJ, Singh S, Bharti N, Jiang Y.

Synthesis (Stuttg). 2010;2010(21):3631-3636.

8.

Vibriobactin antibodies: a vaccine strategy.

Bergeron RJ, Bharti N, Singh S, McManis JS, Wiegand J, Green LG.

J Med Chem. 2009 Jun 25;52(12):3801-13. doi: 10.1021/jm900119q.

9.

Desferrithiocin analogue uranium decorporation agents.

Bergeron RJ, Wiegand J, Singh S.

Int J Radiat Biol. 2009 Apr;85(4):348-61. doi: 10.1080/09553000902781089.

10.

Desferrithiocin analogues and nephrotoxicity.

Bergeron RJ, Wiegand J, McManis JS, Bharti N, Singh S.

J Med Chem. 2008 Oct 9;51(19):5993-6004. doi: 10.1021/jm8003398. Epub 2008 Sep 13.

11.

Design, synthesis, and testing of non-nephrotoxic desazadesferrithiocin polyether analogues.

Bergeron RJ, Wiegand J, McManis JS, Bharti N, Singh S.

J Med Chem. 2008 Jul 10;51(13):3913-23. doi: 10.1021/jm800154m. Epub 2008 Jun 6.

12.

Impact of the 3,6,9-trioxadecyloxy group on desazadesferrithiocin analogue iron clearance and organ distribution.

Bergeron RJ, Wiegand J, Bharti N, Singh S, Rocca JR.

J Med Chem. 2007 Jul 12;50(14):3302-13. Epub 2007 Jun 12.

13.

The design, synthesis, and evaluation of organ-specific iron chelators.

Bergeron RJ, Wiegand J, McManis JS, Bharti N.

J Med Chem. 2006 Nov 30;49(24):7032-43.

14.

(S)-4,5-dihydro-2-(2-hydroxy-4-hydroxyphenyl)-4-methyl-4-thiazolecarboxylic acid polyethers: a solution to nephrotoxicity.

Bergeron RJ, Wiegand J, McManis JS, Vinson JR, Yao H, Bharti N, Rocca JR.

J Med Chem. 2006 May 4;49(9):2772-83.

15.

Polyamine-vectored iron chelators: the role of charge.

Bergeron RJ, Bharti N, Wiegand J, McManis JS, Yao H, Prokai L.

J Med Chem. 2005 Jun 16;48(12):4120-37.

PMID:
15943485
16.

Synthesis and biological evaluation of aminopolyamines.

Bergeron RJ, Huang G, McManis JS, Yao H, Nguyen JN.

J Med Chem. 2005 May 5;48(9):3099-102.

PMID:
15857111
17.

Partition-variant desferrithiocin analogues: organ targeting and increased iron clearance.

Bergeron RJ, Wiegand J, McManis JS, Weimar WR, Park JH, Eiler-McManis E, Bergeron J, Brittenham GM.

J Med Chem. 2005 Feb 10;48(3):821-31.

PMID:
15689166
18.

Comparison of iron chelator efficacy in iron-overloaded beagle dogs and monkeys (Cebus apella).

Bergeron RJ, Wiegand J, Weimar WR, Lindstrom TC, Fannin TL, Ratliff-Thompson K.

Comp Med. 2004 Dec;54(6):664-72.

PMID:
15679265
19.

Polyamine-iron chelator conjugate.

Bergeron RJ, McManis JS, Franklin AM, Yao H, Weimar WR.

J Med Chem. 2003 Dec 4;46(25):5478-83.

PMID:
14640556
20.

Iron chelation promoted by desazadesferrithiocin analogs: An enantioselective barrier.

Bergeron RJ, Wiegand J, Weimar WR, McManis JS, Smith RE, Abboud KA.

Chirality. 2003 Aug;15(7):593-9.

PMID:
12840823
21.

Methoxylation of desazadesferrithiocin analogues: enhanced iron clearing efficiency.

Bergeron RJ, Wiegand J, McManis JS, Bussenius J, Smith RE, Weimar WR.

J Med Chem. 2003 Apr 10;46(8):1470-7.

PMID:
12672247
22.

Prevention of acetic acid-induced colitis by desferrithiocin analogs in a rat model.

Bergeron RJ, Wiegand J, Weimar WR, Nguyen JN, Sninsky CA.

Dig Dis Sci. 2003 Feb;48(2):399-407.

PMID:
12643622
23.

Structure-activity relationships among desazadesferrithiocin analogues.

Bergeron RJ, Wiegand J, McManis JS, Weimar WR, Huang G.

Adv Exp Med Biol. 2002;509:167-84. Review.

PMID:
12572994
24.

Desferrithiocin analogue based hexacoordinate iron(III) chelators.

Bergeron RJ, Huang G, Weimar WR, Smith RE, Wiegand J, McManis JS.

J Med Chem. 2003 Jan 2;46(1):16-24.

PMID:
12502356
25.

Measurement of arsenic bioavailability in soil using a primate model.

Roberts SM, Weimar WR, Vinson JR, Munson JW, Bergeron RJ.

Toxicol Sci. 2002 Jun;67(2):303-10.

PMID:
12011490
27.

Control of irritable bowel syndrome with polyamine analogs: a structure-activity study.

Bergeron RJ, Wiegand J, Fannin TL.

Dig Dis Sci. 2001 Dec;46(12):2615-23.

PMID:
11768250
28.

Significance of asymmetric sites in choosing siderophores as deferration agents.

Bergeron RJ, Xin MG, Weimar WR, Smith RE, Wiegand J.

J Med Chem. 2001 Jul 19;44(15):2469-78.

PMID:
11448229
29.

Synthesis and evaluation of hydroxylated polyamine analogues as antiproliferatives.

Bergeron RJ, Müller R, Huang G, McManis JS, Algee SE, Yao H, Weimar WR, Wiegand J.

J Med Chem. 2001 Jul 19;44(15):2451-9.

PMID:
11448227
30.

Polyamine analogue antidiarrheals: a structure-activity study.

Bergeron RJ, Wiegand J, McManis JS, Weimar WR, Smith RE, Algee SE, Fannin TL, Slusher MA, Snyder PS.

J Med Chem. 2001 Jan 18;44(2):232-44.

PMID:
11170633
31.

Metabolism and pharmacokinetics of N1,N11-diethylnorspermine in a Cebus apella primate model.

Bergeron RJ, Merriman RL, Olson SG, Wiegand J, Bender J, Streiff RR, Weimar WR.

Cancer Res. 2000 Aug 15;60(16):4433-9.

32.

Synthesis and evaluation of hydroxylated polyamine analogues as antiproliferatives.

Bergeron RJ, Müller R, Bussenius J, McManis JS, Merriman RL, Smith RE, Yao H, Weimar WR.

J Med Chem. 2000 Jan 27;43(2):224-35.

PMID:
10649978
33.

Pharmacokinetics of orally administered desferrithiocin analogs in cebus apella primates.

Bergeron RJ, Weimar WR, Wiegand J.

Drug Metab Dispos. 1999 Dec;27(12):1496-8.

PMID:
10570032
34.

Evaluation of the desferrithiocin pharmacophore as a vector for hydroxamates.

Bergeron RJ, McManis JS, Bussenius J, Brittenham GM, Wiegand J.

J Med Chem. 1999 Jul 29;42(15):2881-6.

PMID:
10425097
35.

Effects of C-4 stereochemistry and C-4' hydroxylation on the iron clearing efficiency and toxicity of desferrithiocin analogues.

Bergeron RJ, Wiegand J, McManis JS, McCosar BH, Weimar WR, Brittenham GM, Smith RE.

J Med Chem. 1999 Jul 1;42(13):2432-40.

PMID:
10395484
36.

Polyamine analogue induction of the p53-p21WAF1/CIP1-Rb pathway and G1 arrest in human melanoma cells.

Kramer DL, Vujcic S, Diegelman P, Alderfer J, Miller JT, Black JD, Bergeron RJ, Porter CW.

Cancer Res. 1999 Mar 15;59(6):1278-86.

37.

Desazadesmethyldesferrithiocin analogues as orally effective iron chelators.

Bergeron RJ, Wiegand J, Weimar WR, Vinson JR, Bussenius J, Yao GW, McManis JS.

J Med Chem. 1999 Jan 14;42(1):95-108.

PMID:
9888836
38.
39.

Polyamine analogue antiarrhythmics.

Bergeron RJ, Wiegand J, Weimar WR, Snyder PS.

Pharmacol Res. 1998 Nov;38(5):367-80.

PMID:
9806817
40.

Effect of polyamine analogues on hypusine content in JURKAT T-cells.

Bergeron RJ, Weimar WR, Müller R, Zimmerman CO, McCosar BH, Yao H, Smith RE.

J Med Chem. 1998 Sep 24;41(20):3901-8.

PMID:
9748365
41.

Synthesis of reagents for the construction of hypusine and deoxyhypusine peptides and their application as peptidic antigens.

Bergeron RJ, Weimar WR, Müller R, Zimmerman CO, McCosar BH, Yao H, Smith RE.

J Med Chem. 1998 Sep 24;41(20):3888-900.

PMID:
9748364
42.
43.

The origin of the differences in (R)- and (S)-desmethyldesferrithiocin. Iron-clearing properties.

Bergeron RJ, Wiegand J, Ratliff-Thompson K, Weimar WR.

Ann N Y Acad Sci. 1998 Jun 30;850:202-16.

PMID:
9668541
44.

HBED: A potential alternative to deferoxamine for iron-chelating therapy.

Bergeron RJ, Wiegand J, Brittenham GM.

Blood. 1998 Feb 15;91(4):1446-52.

45.

Human prostatic carcinoma cell lines display altered regulation of polyamine transport in response to polyamine analogs and inhibitors.

Mi Z, Kramer DL, Miller JT, Bergeron RJ, Bernacki R, Porter CW.

Prostate. 1998 Jan 1;34(1):51-60.

PMID:
9428388
46.

The influence of molecular conformation upon the self-assembly of cyclohexane diamide diacids.

Bergeron RJ, Yao GW, Erdos GW, Milstein S, Gao F, Rocca J, Weimar WR, Price HL, Phanstiel O 4th.

Bioorg Med Chem. 1997 Nov;5(11):2049-61.

PMID:
9416422
47.

Effects of novel spermine analogues on cell cycle progression and apoptosis in MALME-3M human melanoma cells.

Kramer DL, Fogel-Petrovic M, Diegelman P, Cooley JM, Bernacki RJ, McManis JS, Bergeron RJ, Porter CW.

Cancer Res. 1997 Dec 15;57(24):5521-7.

48.

Structural basis for differential induction of spermidine/spermine N1-acetyltransferase activity by novel spermine analogs.

Fogel-Petrovic M, Kramer DL, Vujcic S, Miller J, McManis JS, Bergeron RJ, Porter CW.

Mol Pharmacol. 1997 Jul;52(1):69-74.

PMID:
9224814
49.

Development of a Hypusine Reagent for Peptide Synthesis.

Bergeron RJ, Ludin C, Müller R, Smith RE, Phanstiel O IV.

J Org Chem. 1997 May 16;62(10):3285-3290.

PMID:
11671715
50.

A comparison of structure-activity relationships between spermidine and spermine analogue antineoplastics.

Bergeron RJ, Feng Y, Weimar WR, McManis JS, Dimova H, Porter C, Raisler B, Phanstiel O.

J Med Chem. 1997 May 9;40(10):1475-94.

PMID:
9154970

Supplemental Content

Loading ...
Support Center